ArticleJournal for immunotherapy of cancer2019

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.

Suzanne Thomas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.